BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Where I live in Ontario (15 million) run out vacci next week

<< Previous

Bullboard Posts

Next >>

Comment by ChaseAcklandon Jan 08, 2021 11:17am

85 Views

Post# 32253885

RE:Where I live in Ontario (15 million) run out vacci next week

And not just years of vaccines needed, but a range of different technical approaches. IMO, I dont think SARS2 will have a 'one size fits all' solution. A lot of variability among recipients may require a range of vaccine options. World was so unprepared for this...governments and global pharma should have heeded the writing on the wall with the 2002 SARS-CoV-1 outbreak.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading